Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

HLXB

Helix Acquisition Corp. II

May 06 • 04:00PM ET

10.24

Dollar change -0.10
Percentage change -0.97	%

Financial • Shell Companies • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: BMED

Index	-	P/E	-	EPS (ttm)	-	Insider Own	29.87%	Shs Outstand	16.48M	Perf Week	-0.19%
Market Cap	215.96M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	14.79M	Perf Month	-0.69%
Income	-	PEG	-	EPS next Q	-	Inst Own	29.77%	Short Float	0.01%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.01	Perf Half Y	-
Book/sh	-0.00	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.00M	Perf Year	-
Cash/sh	0.00	P/C	-	EPS next 5Y	-	ROE	-	52W Range	10.03 - 10.83	Perf YTD	0.49%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-5.43%	Beta	-
Dividend TTM	-	Quick Ratio	0.00	Sales past 5Y	0.00%	Gross Margin	-	52W Low	2.09%	ATR (14)	0.10
Dividend Ex-Date	-	Current Ratio	0.00	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	46.35	Volatility	0.73% 0.66%
Employees	-	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-	Payout	-	Rel Volume	0.01	Prev Close	10.34
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	107.74K	Price	10.24
SMA20	-0.78%	SMA50	-0.96%	SMA200	-0.97%	Trades		Volume	878	Change	-0.97%

Feb-29-24 03:01AM	5 Stocks With Heavy Insider Buying In 2024 (Insider Monkey)
Feb-14-24 07:30AM	Helix Acquisition Corp. II Announces Closing of $184 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares (Business Wire)
Feb-09-24 07:30AM	Helix Acquisition Corp. II Announces Pricing of Upsized $160 Million Initial Public Offering (Business Wire)

Helix Acquisition Corp. II operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was formed on June 15, 2021 and is headquartered in Boston, MA.

Open in Screener

MLTX

MoonLake Immunotherapeutics

May 06 • 04:00PM ET

44.52

Dollar change -0.74
Percentage change -1.63	%

Healthcare • Biotechnology • Switzerland • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

MLTX MoonLake Immunotherapeutics daily Stock Chart

Held by: VHT SBIO NUSC ONEQ SMMV ESML VT GURU FHLC USVM

Index	-	P/E	-	EPS (ttm)	-0.76	Insider Own	21.27%	Shs Outstand	60.47M	Perf Week	6.58%
Market Cap	2.80B	Forward P/E	-	EPS next Y	-1.76	Insider Trans	-3.50%	Shs Float	49.50M	Perf Month	-5.62%
Income	-36.01M	PEG	-	EPS next Q	-0.19	Inst Own	93.95%	Short Float	14.66%	Perf Quarter	-24.36%
Sales	0.00M	P/S	-	EPS this Y	-54.89%	Inst Trans	0.54%	Short Ratio	15.41	Perf Half Y	-5.94%
Book/sh	8.20	P/B	5.43	EPS next Y	-55.61%	ROA	-11.94%	Short Interest	7.26M	Perf Year	81.27%
Cash/sh	8.13	P/C	5.48	EPS next 5Y	-	ROE	-13.22%	52W Range	22.12 - 64.98	Perf YTD	-26.28%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-7.23%	52W High	-31.49%	Beta	1.29
Dividend TTM	-	Quick Ratio	51.59	Sales past 5Y	0.00%	Gross Margin	-	52W Low	101.27%	ATR (14)	1.95
Dividend Ex-Date	-	Current Ratio	51.59	EPS Y/Y TTM	31.09%	Oper. Margin	0.00%	RSI (14)	49.93	Volatility	4.02% 3.81%
Employees	50	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.29	Target Price	73.38
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	59.36%	Payout	-	Rel Volume	0.29	Prev Close	45.26
Sales Surprise	-	EPS Surprise	47.92%	Sales Q/Q	-	Earnings	Feb 29 BMO	Avg Volume	470.98K	Price	44.52
SMA20	2.51%	SMA50	-4.72%	SMA200	-15.27%	Trades		Volume	135,711	Change	-1.63%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-02-24	Initiated	Goldman	Neutral	$62
Feb-15-24	Initiated	Wolfe Research	Outperform	$77
Dec-08-23	Initiated	Citigroup	Buy	$72
Nov-02-23	Initiated	Stifel	Buy	$74
Sep-14-23	Downgrade	Bryan Garnier	Buy → Neutral
Aug-31-23	Initiated	Needham	Buy	$76
Jun-15-23	Initiated	Barclays	Equal Weight	$28
May-01-23	Initiated	Guggenheim	Buy	$51
Mar-22-23	Initiated	Wedbush	Outperform	$33
Mar-09-23	Initiated	BTIG Research	Buy	$36
Feb-14-23	Initiated	Cantor Fitzgerald	Overweight	$23
Feb-02-23	Initiated	Bryan Garnier	Buy	$22
Nov-11-22	Initiated	Jefferies	Buy	$16
Aug-25-22	Initiated	SVB Leerink	Outperform	$17
Jul-21-22	Initiated	H.C. Wainwright	Buy	$28
Jul-07-22	Initiated	Cowen	Outperform

Show Previous Ratings

Apr-10-24 07:00AM	MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions (GlobeNewswire)
Mar-11-24 04:25PM	MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test (Investor's Business Daily)
Mar-10-24 12:00PM	MoonLake announces significant improvements with Nanobody sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day (GlobeNewswire)
Mar-04-24 08:00AM	MoonLake Immunotherapeutics to present MIRA trial data of Nanobody sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024 (GlobeNewswire)
Mar-01-24 12:38AM	Insider Sell: CEO Santos da Silva Jorge Sells 123,615 Shares of MoonLake Immunotherapeutics (MLTX) (GuruFocus.com) +5.56%
08:00AM	Loading…
Feb-29-24 08:00AM	MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10 (GlobeNewswire) -15.09%
Feb-26-24 08:00AM	MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody sonelokimab (SLK) in Hidradenitis Suppurativa (HS) (GlobeNewswire)
Feb-20-24 11:44PM	Insider Sell: CEO Santos da Silva Jorge Sells 60,000 Shares of MoonLake Immunotherapeutics (GuruFocus.com) -7.88%
Jan-11-24 09:55AM	Wall Street Analysts Believe MoonLake Immunotherapeutics (MLTX) Could Rally 26.97%: Here's is How to Trade (Zacks)
Jan-10-24 08:42AM	Is MoonLake Immunotherapeutics (MLTX) Stock a Solid Choice Right Now? (Zacks)
Dec-22-23 03:01PM	CFO Matthias Bodenstedt Sells 100,000 Shares of MoonLake Immunotherapeutics (GuruFocus.com)
Nov-14-23 12:13PM	MoonLake Immunotherapeutics (MLTX) Posts Q3 2023 Results: Clinical Progress Amid Controlled Expenses (GuruFocus.com)
08:00AM	MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-06-23 04:03PM	Why Former Highflier MoonLake Plummeted 29% After A Recent Run (Investor's Business Daily) -29.11%
09:46AM	Top-Rated MoonLake Stock Crashes On Mixed Test Results For Arthritis Drug (Investor's Business Daily)
11:00AM	Loading…
Nov-05-23 11:00AM	MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody sonelokimab in active psoriatic arthritis (GlobeNewswire)
Oct-26-23 10:33AM	12 Best Performing NASDAQ Stocks in 2023 (Insider Monkey)
Oct-20-23 01:22PM	12 Best Performing Biotech Stocks in 2023 (Insider Monkey)
Oct-16-23 04:30PM	MoonLake Immunotherapeutics' Lead Skin Disorder Candidate Continues to Deliver on Best-Efficacy Profile: Analyst (Benzinga) +10.72%
04:04PM	Why Top-Notch MoonLake Surged 11% And Almost Broke Out (Investor's Business Daily)
10:41AM	Why Top 1% Biotech MoonLake Just Surged Within Striking Distance Of A Breakout (Investor's Business Daily)
Oct-15-23 09:03AM	MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa (GlobeNewswire)
Oct-11-23 10:15AM	MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress (GlobeNewswire) -7.06%
Oct-04-23 07:01AM	Phase 2 MIRA primary analysis trial results (12-week) for MoonLake's Nanobody sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress (GlobeNewswire)
Sep-27-23 09:24PM	7 Strong Buy Biotech Stocks to Rejuvenate Your Portfolio (InvestorPlace)
Sep-18-23 05:09PM	These 7 Stocks Are Outperforming Nvidia In 2023 (Investor's Business Daily)
Sep-13-23 09:45AM	ACELYRIN (SLRN) Fails to Meet Goal in HS Study, Stock Down 54% (Zacks)
Sep-12-23 04:07PM	The Surprising Acelyrin News That Sent Rival MoonLake, A Top 1% Stock, Soaring 10% (Investor's Business Daily) +9.88%
11:40AM	Why Shares of MoonLake Immunotherapeutics Are Rising Tuesday (Motley Fool)
Sep-06-23 07:00AM	MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11 (GlobeNewswire)
02:00PM	Loading…
Sep-01-23 02:00PM	Top Growth Stocks for September 2023 (Investopedia) -6.32%
11:30AM	Top Stocks for September 2023 (Investopedia)
Aug-31-23 09:53AM	Palantir downgraded, Shopify upgraded: Wall Street's top analyst calls (The Fly)
08:30AM	The 7 Most Promising Momentum Stocks to Own Now (InvestorPlace)
Aug-16-23 03:12PM	15 Best Performing Stocks in the Last 3 Months (Insider Monkey)
Aug-15-23 07:00AM	Get In on This Skin Disease Drug Before Big Pharma Does (The Wall Street Journal)
Aug-10-23 07:00AM	MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Jul-25-23 08:00AM	MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts (GlobeNewswire)
Jul-14-23 03:38PM	Exclusive-MoonLake Immunotherapeutics explores sale-sources (Reuters) +8.39%
Jul-03-23 09:45AM	MoonLake Immunotherapeutics' (NASDAQ:MLTX) high hedge funds ownership speaks for itself as stock continues to impress, up 11% over last week (Simply Wall St.)
Jun-29-23 02:41PM	Why MoonLake Immunotherapeutics Stock Skyrocketed This Week (Motley Fool)
Jun-28-23 05:00AM	MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares (GlobeNewswire)
Jun-27-23 06:56PM	Why MoonLake Immunotherapeutics Was Such a Healthy Stock Today (Motley Fool) +12.71%
Jun-26-23 04:07PM	Why Mutual Fund Darling And Top 1% Stock MoonLake Just Catapulted To A Record (Investor's Business Daily) +77.55%
04:01PM	MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering (GlobeNewswire)
02:36PM	Why Shares of MoonLake Immunotherapeutics Skyrocketed Monday (Motley Fool)
09:01AM	Lucid Stock Moved Into the Fast Lane, but This Nasdaq Biotech Was Monday's Big Winner (Motley Fool)
Jun-25-23 09:00AM	MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa (GlobeNewswire)
May-26-23 08:50AM	MoonLake Immunotherapeutics (MLTX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-14-23 09:43AM	TipRanks Perfect 10 List: 3 Top-Rated Stocks That Tick All the Right Boxes (TipRanks)
May-12-23 07:45AM	MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
May-11-23 08:32AM	Why MoonLake (MLTX) Might Surprise This Earnings Season (Zacks) -5.45%
May-10-23 08:50AM	Here's Why Momentum in MoonLake Immunotherapeutics (MLTX) Should Keep going (Zacks)
May-03-23 06:45AM	MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply (GlobeNewswire) +7.55%
Apr-24-23 08:50AM	MoonLake Immunotherapeutics (MLTX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks) +10.08%
Apr-19-23 08:16AM	MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today (GlobeNewswire)
Apr-05-23 12:00PM	What Makes MoonLake Immunotherapeutics (MLTX) a New Buy Stock (Zacks) +6.84%
Mar-20-23 07:45AM	MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update (GlobeNewswire) -7.87%
Feb-14-23 01:02PM	Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path (Benzinga) +8.16%
Feb-02-23 08:00AM	MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa (GlobeNewswire)
Dec-14-22 08:00AM	MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis (GlobeNewswire)
Nov-14-22 08:00AM	MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update (GlobeNewswire)
Sep-26-22 10:57AM	FDA Clears MoonLake's Nanobody Study For Arthritis Patients (Benzinga)
08:00AM	MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis (GlobeNewswire)
Jul-26-22 08:00AM	MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH (GlobeNewswire) +13.31%
Jul-25-22 10:11AM	Do Insiders Own Lots Of Shares In MoonLake Immunotherapeutics (NASDAQ:MLTX)? (Simply Wall St.)
May-12-22 07:00AM	MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (GlobeNewswire)

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Santos da Silva Jorge	Chief Executive Officer	Feb 29 '24	Sale	55.89	4,740	264,919	2,982,814	Feb 29 07:56 PM
Santos da Silva Jorge	Chief Executive Officer	Feb 28 '24	Sale	55.00	56,065	3,083,575	2,987,554	Feb 29 07:56 PM
Reich Kristian	Chief Scientific Officer	Feb 28 '24	Sale	55.00	31,910	1,755,050	2,925,573	Feb 29 07:53 PM
Reich Kristian	Chief Scientific Officer	Feb 28 '24	Sale	55.00	28,090	1,544,950	41,981	Feb 29 07:53 PM
Santos da Silva Jorge	Chief Executive Officer	Feb 27 '24	Sale	55.00	62,810	3,454,550	3,043,619	Feb 29 07:56 PM
Reich Kristian	Chief Scientific Officer	Feb 27 '24	Sale	55.00	29,491	1,622,005	2,957,483	Feb 29 07:53 PM
Reich Kristian	Chief Scientific Officer	Feb 27 '24	Sale	55.00	29,431	1,618,705	70,071	Feb 29 07:53 PM
Santos da Silva Jorge	Chief Executive Officer	Feb 21 '24	Sale	55.27	1,125	62,179	3,106,429	Feb 23 04:48 PM
Reich Kristian	Chief Scientific Officer	Feb 21 '24	Sale	55.30	569	31,466	99,502	Feb 22 06:32 PM
Reich Kristian	Chief Scientific Officer	Feb 21 '24	Sale	55.31	509	28,153	2,986,974	Feb 22 06:32 PM
Santos da Silva Jorge	Chief Executive Officer	Feb 20 '24	Sale	57.44	20,000	1,148,800	3,107,554	Feb 20 06:36 PM
Reich Kristian	Chief Scientific Officer	Feb 20 '24	Sale	57.45	10,000	574,500	2,987,483	Feb 22 06:32 PM
Reich Kristian	Chief Scientific Officer	Feb 20 '24	Sale	57.43	10,000	574,300	100,071	Feb 22 06:32 PM
Santos da Silva Jorge	Chief Executive Officer	Feb 16 '24	Sale	60.15	20,000	1,203,000	3,127,554	Feb 20 06:36 PM
Reich Kristian	Chief Scientific Officer	Feb 16 '24	Sale	60.15	10,000	601,500	2,997,483	Feb 16 06:02 PM
Reich Kristian	Chief Scientific Officer	Feb 16 '24	Sale	60.15	10,000	601,500	110,071	Feb 16 06:02 PM
Santos da Silva Jorge	Chief Executive Officer	Feb 15 '24	Sale	60.18	20,000	1,203,600	3,147,554	Feb 20 06:36 PM
Reich Kristian	Chief Scientific Officer	Feb 15 '24	Sale	60.17	10,000	601,700	3,007,483	Feb 16 06:02 PM
Reich Kristian	Chief Scientific Officer	Feb 15 '24	Sale	60.16	10,000	601,600	120,071	Feb 16 06:02 PM
Reich Kristian	Chief Scientific Officer	Feb 14 '24	Sale	62.43	10,000	624,300	130,071	Feb 16 06:02 PM
Reich Kristian	Chief Scientific Officer	Feb 14 '24	Sale	62.42	10,000	624,200	3,017,483	Feb 16 06:02 PM
Bodenstedt Matthias	Chief Financial Officer	Dec 20 '23	Sale	58.34	5,264	307,102	520,903	Dec 21 04:01 PM
Bodenstedt Matthias	Chief Financial Officer	Dec 19 '23	Sale	59.22	94,736	5,610,266	526,167	Dec 21 04:01 PM
Chen Bihua	10% Owner	Oct 05 '23	Buy	59.90	58,839	3,524,297	8,494,151	Oct 10 04:00 PM
Chen Bihua	10% Owner	Oct 04 '23	Buy	57.32	67,814	3,887,017	8,435,312	Oct 04 05:52 PM
Chen Bihua	10% Owner	Oct 03 '23	Buy	57.25	150,487	8,615,682	8,367,498	Oct 04 05:52 PM
Chen Bihua	10% Owner	Oct 02 '23	Buy	57.37	74,911	4,297,644	8,217,011	Oct 04 05:52 PM
Chen Bihua	10% Owner	Jun 30 '23	Buy	50.00	800,000	40,000,000	4,927,100	Jul 05 04:05 PM
Chen Bihua	10% Owner	Jun 26 '23	Buy	45.63	450,000	20,535,012	4,127,100	Jun 28 06:28 PM

Open in Screener

BMEA

Biomea Fusion Inc

May 06 • 04:00PM ET

12.26

Dollar change -0.09
Percentage change -0.73	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

BMEA Biomea Fusion Inc daily Stock Chart

Held by: VTI IWM VXF LABU IBB IWO SCHA VHT VTWO IWC

Index	RUT	P/E	-	EPS (ttm)	-3.56	Insider Own	22.76%	Shs Outstand	35.87M	Perf Week	14.05%
Market Cap	440.62M	Forward P/E	-	EPS next Y	-4.01	Insider Trans	0.00%	Shs Float	27.76M	Perf Month	-3.69%
Income	-127.27M	PEG	-	EPS next Q	-1.08	Inst Own	87.83%	Short Float	49.78%	Perf Quarter	-34.09%
Sales	0.00M	P/S	-	EPS this Y	-22.70%	Inst Trans	-10.84%	Short Ratio	13.51	Perf Half Y	21.87%
Book/sh	3.77	P/B	3.26	EPS next Y	5.08%	ROA	-90.54%	Short Interest	13.82M	Perf Year	-61.70%
Cash/sh	4.03	P/C	3.04	EPS next 5Y	-	ROE	-116.52%	52W Range	8.12 - 43.69	Perf YTD	-15.56%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-204.86%	ROI	-88.85%	52W High	-71.94%	Beta	-0.34
Dividend TTM	-	Quick Ratio	5.84	Sales past 5Y	0.00%	Gross Margin	-	52W Low	50.89%	ATR (14)	0.95
Dividend Ex-Date	-	Current Ratio	5.84	EPS Y/Y TTM	-10.86%	Oper. Margin	0.00%	RSI (14)	49.05	Volatility	7.87% 6.87%
Employees	103	Debt/Eq	0.08	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.38	Target Price	49.50
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	-10.84%	Payout	-	Rel Volume	0.49	Prev Close	12.35
Sales Surprise	-	EPS Surprise	-9.64%	Sales Q/Q	-	Earnings	May 02 AMC	Avg Volume	1.02M	Price	12.26
SMA20	5.02%	SMA50	-13.93%	SMA200	-16.71%	Trades		Volume	498,251	Change	-0.73%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-02-24	Downgrade	JP Morgan	Overweight → Neutral	$51 → $14
Feb-06-24	Initiated	Truist	Buy	$55
Jul-27-23	Initiated	Scotiabank	Sector Outperform	$41
Jun-26-23	Downgrade	Jefferies	Buy → Hold
May-12-23	Initiated	Barclays	Overweight	$50
Mar-29-23	Reiterated	Oppenheimer	Outperform	$25 → $47
Mar-28-23	Reiterated	H.C. Wainwright	Buy	$37 → $44
Feb-24-23	Initiated	Citigroup	Buy	$20
Jun-02-22	Resumed	H.C. Wainwright	Buy	$16
Jan-12-22	Initiated	H.C. Wainwright	Buy	$13
Dec-17-21	Initiated	Oppenheimer	Outperform	$22
May-11-21	Initiated	Piper Sandler	Overweight	$27
May-11-21	Initiated	JP Morgan	Overweight	$26
May-11-21	Initiated	Jefferies	Buy	$26

Show Previous Ratings

May-02-24 10:54PM	BMEA Stock Earnings: Biomea Fusion Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire)
May-01-24 04:10PM	Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.73%
Apr-19-24 11:02AM	12 Most Shorted Stocks in 2024 (Insider Monkey)
Apr-01-24 04:10PM	Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:52PM	Loading…
01:52PM	BMEA Stock Earnings: Biomea Fusion Misses EPS for Q4 2023 (InvestorPlace)
09:02AM	Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219 (GlobeNewswire)
09:00AM	Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Mar-07-24 02:52PM	7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode (InvestorPlace)
Mar-06-24 03:04AM	Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219's 28-Day Treatment Cycle, Supporting Improved Pancreatic Function (GlobeNewswire) -9.82%
Mar-01-24 04:16PM	Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-19-24 03:18PM	Feeling Shut Out? 3 Sizzling Stocks and the Pull-Back Prices to Watch For (InvestorPlace)
Feb-18-24 03:41PM	3 Speculative Stocks That Could Make Your February Unforgettable (InvestorPlace)
Feb-08-24 04:19PM	3 Long-Term Stocks to Buy on the Dip: February 2024 (InvestorPlace)
Jan-09-24 11:02AM	Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
09:00AM	Loading…
Jan-08-24 09:00AM	Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219 (GlobeNewswire) +8.36%
Jan-02-24 04:05PM	Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-23 09:27AM	Biomea Fusion (BMEA) Stock Surges 41% in a Month: Here's Why (Zacks) +15.29%
Dec-11-23 09:25AM	Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH Annual Meeting (GlobeNewswire) -30.31%
Dec-09-23 05:30PM	Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts (GlobeNewswire)
Dec-08-23 09:00AM	Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) (GlobeNewswire) +12.38%
Dec-07-23 09:15AM	Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) (GlobeNewswire) -18.54%
Dec-05-23 08:30AM	Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes (GlobeNewswire)
Nov-27-23 08:30AM	Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024 (GlobeNewswire)
Nov-16-23 08:30AM	Biomea Fusion Abstract BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control' Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (GlobeNewswire)
Nov-08-23 04:05PM	Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) (GlobeNewswire)
Nov-02-23 09:05AM	Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023 (GlobeNewswire)
Nov-01-23 05:58AM	Biomea Fusion Inc (BMEA) Reports Q3 2023 Financial Results and Corporate Highlights (GuruFocus.com)
Oct-31-23 01:19AM	The Biomea Fusion Inc (BMEA) Company: A Short SWOT Analysis (GuruFocus.com) -7.59%
Oct-30-23 04:01PM	Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
10:13AM	Loading…
Oct-18-23 10:13AM	Biomea (BMEA) Doses First Patient in Leukemia Study, Stock Up (Zacks)
Oct-17-23 08:30AM	Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103) (GlobeNewswire) +6.72%
Oct-05-23 09:40AM	Is Ayr Wellness Inc. (AYRWF) Outperforming Other Medical Stocks This Year? (Zacks)
08:30AM	Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes (GlobeNewswire)
Sep-28-23 08:30AM	Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study (GlobeNewswire)
Aug-31-23 08:30AM	Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer (GlobeNewswire)
Aug-23-23 12:26PM	11 Best High Short Interest Stocks To Buy Now (Insider Monkey)
Jul-31-23 04:01PM	Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire)
Jul-24-23 09:00AM	BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population (GlobeNewswire) -14.58%
Jul-13-23 10:08AM	We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully (Simply Wall St.)
Jun-26-23 10:54AM	Biomea Fusion Stock Is Trading Higher Today - Here's Why (Benzinga) -20.39%
Jun-23-23 09:54PM	Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3 Demonstrated a 90% Response Rate and 70% Maintained or Improved Time in (Normal Glucose) Range, While Off-Treatment (GlobeNewswire) -5.89%
Jun-20-23 04:30PM	Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023 (GlobeNewswire)
Jun-05-23 06:44AM	Daily Vickers Top Buyers & Sellers for 06/05/2023 (Argus Research)
May-18-23 06:39AM	Daily Vickers Top Buyers & Sellers for 05/18/2023 (Argus Research)
May-14-23 09:43AM	TipRanks Perfect 10 List: 3 Top-Rated Stocks That Tick All the Right Boxes (TipRanks)
May-11-23 08:39AM	Top Healthcare Stocks for May 2023 (Investopedia)
May-02-23 04:01PM	Biomea Fusion Reports First Quarter 2023 Financial Results and Corporate Highlights (GlobeNewswire) -8.55%
May-01-23 08:30AM	Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia (GlobeNewswire) +7.60%
Apr-27-23 07:02AM	Daily Vickers Top Buyers & Sellers for 04/27/2023 (Argus Research) -8.20%
Apr-23-23 09:28AM	individual investors who own 31% along with institutions invested in Biomea Fusion, Inc. (NASDAQ:BMEA) saw increase in their holdings value last week (Simply Wall St.)
Apr-19-23 02:42PM	Top Biotech Stocks for Q2 2023 (Investopedia) +5.77%
08:30AM	Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes, at the ADA 83rd Scientific Sessions 2023 in June (GlobeNewswire)
Apr-13-23 04:30PM	Biomea Fusion To Present Two Preclinical Posters at the 114th AACR Annual Meeting (GlobeNewswire)
09:00AM	Biomea Fusion Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Apr-07-23 07:44AM	Daily Vickers Top Buyers & Sellers for 04/07/2023 (Argus Research)
Mar-30-23 02:35PM	Why Biomea Fusion Stock Crushed It This Week (Motley Fool)
Mar-29-23 11:15PM	Biomea Fusion Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) +5.34%
12:01PM	Biomea (BMEA) Up 99% on Upbeat Data From Type II Diabetes Study (Zacks)
11:24AM	Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback (Zacks)
06:30AM	Biomea Fusion Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Mar-28-23 04:02PM	Biomea Fusion Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights (GlobeNewswire) +99.03%
08:00AM	Biomea Fusion Announces Positive Data from Initial Cohorts of Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes; 100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28 (GlobeNewswire)
Mar-23-23 08:00AM	Biomea Fusion to Host Conference Call and Webcast to Discuss Initial Phase II Clinical Data for BMF-219 in Subjects with Type 2 Diabetes on March 28th, 2023 at 8:30 a.m. ET (GlobeNewswire) +5.26%
Mar-21-23 09:40AM	Has Aspira Women's Health (AWH) Outpaced Other Medical Stocks This Year? (Zacks)
Mar-20-23 08:50AM	What Makes Biomea Fusion, Inc. (BMEA) a Good Fit for 'Trend Investing' (Zacks)
Mar-02-23 08:30AM	Biomea Fusion To Participate In Upcoming Investor Events (GlobeNewswire) -8.13%
Jan-20-23 11:30AM	Why Shares of Biomea Fusion Jumped This Week (Motley Fool) +7.44%
Jan-18-23 11:27AM	Biomea (BMEA) Begins Dosing in Lung Cancer Study, Stock Up (Zacks) +13.00%
Jan-17-23 08:00AM	Biomea Fusion Doses First Patient in Phase I/Ib Clinical Trial (COVALENT-102) of BMF-219 in KRAS Mutant Solid Tumors (GlobeNewswire) +11.69%
Jan-09-23 08:00AM	Biomea Fusion to Present at 41st Annual J.P. Morgan Healthcare Conference and Highlight 2023 Corporate Milestones (GlobeNewswire)
Jan-04-23 09:00AM	Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes in the United States in Ongoing Phase I/II (COVALENT-111) Study of BMF-219 (GlobeNewswire) -9.67%
Dec-14-22 04:30PM	Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for Covalent Menin Inhibitor BMF-219 in Type 2 Diabetes (GlobeNewswire)
05:44AM	Here's Why We're Watching Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation (Simply Wall St.)
Dec-12-22 08:00AM	Biomea Fusion Presents at the 2022 ASH Annual Meeting Preclinical Data on BMF-500 Supporting its Potential as the Most Potent and Selective FLT3 Inhibitor to Date (GlobeNewswire)
Nov-14-22 08:12AM	Institutional owners may take dramatic actions as Biomea Fusion, Inc.'s (NASDAQ:BMEA) recent 29% drop adds to one-year losses (Simply Wall St.)
Nov-11-22 08:30AM	Biomea Fusion to Participate in Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire) -6.17%
Nov-07-22 04:27PM	Biomea Fusion Reports Third Quarter 2022 Financial Results and Business Highlights (GlobeNewswire) -10.17%
Nov-03-22 09:19AM	Biomea Fusion to Present Preclinical Data for BMF-500, an Investigational Oral Covalent FLT3 Inhibitor, at the 64th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-22 08:00AM	Biomea Fusion Announces Dosing of First Patient with Type 2 Diabetes and Completion of Phase I Healthy Volunteer Portion of Phase I/II (COVALENT-111) Study of BMF-219 (GlobeNewswire) +7.00%
Oct-27-22 08:00AM	Biomea Fusion Announces First Patient Dosed with Chronic Lymphocytic Leukemia (CLL) in COVALENT-101 Trial (GlobeNewswire)
Oct-14-22 09:00AM	BMF-219 Enters the Clinic for KRAS Solid Tumors (GlobeNewswire)
Sep-22-22 09:30AM	Biomea Fusion Presents New Translational Data at the European Association for the Study of Diabetes (EASD) 2022 in Animal Models and Ex-vivo Human Donor Islets Further Supporting BMF-219s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes (GlobeNewswire)
Sep-20-22 07:30AM	Biomea Fusion Presents New Preclinical Data at the European Association for the Study of Diabetes (EASD) Annual Meeting Describing BMF-219s Potential as a Novel, Oral, Long-Acting Treatment for Type 2 Diabetes (GlobeNewswire)
Sep-19-22 12:01PM	Despite Biomea Fusion, Inc.'s recent decline, insiders have made a around US$30k profit after buying earlier this year. (Simply Wall St.)
Aug-26-22 01:13PM	Biomea Fusion Touts Additional Preclinical Data For Blood Cancer Candidate (Benzinga)
08:30AM	Biomea Fusion Presents Additional Preclinical Data Demonstrating Anti-Tumor Activity and Mechanistic Evidence for BMF-219 in Diffuse Large B-Cell Lymphoma and Multiple Myeloma Models at International Myeloma Society Annual Meeting (GlobeNewswire)
Aug-01-22 04:05PM	Biomea Fusion Reports Second Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
Jul-06-22 02:41PM	Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation (Simply Wall St.)
Jul-01-22 08:30AM	Biomea Fusion Selected for Two Oral Presentations at the European Association for the Study of Diabetes Annual Meeting Describing BMF-219s Potential as a Novel, Oral, Long-Acting, Acute Treatment for Type 2 Diabetes (GlobeNewswire) -6.93%
Jun-22-22 08:30AM	Biomea Fusion Announces First Patient Dosed in Multiple Myeloma Cohort of COVALENT-101 Trial (GlobeNewswire) +13.97%
Jun-06-22 01:10PM	How Much Of Biomea Fusion, Inc. (NASDAQ:BMEA) Do Institutions Own? (Simply Wall St.)
Jun-04-22 11:00AM	Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes (GlobeNewswire)
Jun-02-22 06:00PM	Biomea Fusion to Participate in Jefferies Healthcare Conference (GlobeNewswire) +7.64%
Jun-01-22 08:30AM	Biomea Fusion to Present New Preclinical Data on BMF-219 in Two Diabetic Animal Models at ADA 2022 (GlobeNewswire) -18.94%
May-26-22 06:30PM	Biomea Fusion to Present New Preclinical Data Showing BMF-219s Strong Activity in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Tumor Models at ASCO 2022 (GlobeNewswire)
May-20-22 01:30PM	Biomea Fusion to Attend H.C. Wainwright Global Investment Conference (GlobeNewswire) +8.46%
May-19-22 08:00AM	Biomea Fusion Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3 (GlobeNewswire) +16.18%
May-16-22 07:30AM	Biomea Fusion Reports First Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
May-09-22 04:30PM	Biomea Fusion to Participate in Bank of America Securities 2022 Healthcare Conference (GlobeNewswire)

Biomea Fusion, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic disorders, such as diabetes. It offers its lead product candidate, BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. The company was founded by Thomas Butler and Ramses Erdtmann in August 2017 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
A2A Pharmaceuticals, Inc.	10% Owner	Jun 01 '23	Sale	34.56	50,000	1,728,165	3,500,000	Jun 02 05:00 PM
A2A Pharmaceuticals, Inc.	10% Owner	May 31 '23	Sale	33.81	75,000	2,535,750	3,550,000	Jun 02 05:00 PM
A2A Pharmaceuticals, Inc.	10% Owner	May 12 '23	Sale	33.84	25,000	846,000	3,625,000	May 17 07:13 AM
A2A Pharmaceuticals, Inc.	10% Owner	May 09 '23	Sale	34.50	150,000	5,175,720	3,650,000	May 10 05:19 PM
A2A Pharmaceuticals, Inc.	10% Owner	May 08 '23	Sale	33.99	100,000	3,399,310	3,800,000	May 10 05:19 PM

Open in Screener

ERAS

Erasca Inc

May 06 • 04:00PM ET

2.21

Dollar change +0.07
Percentage change 3.27	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN IBB SCHA VTWO VHT ITOT IWC

Index	RUT	P/E	-	EPS (ttm)	-0.83	Insider Own	40.74%	Shs Outstand	151.09M	Perf Week	8.33%
Market Cap	334.79M	Forward P/E	-	EPS next Y	-0.96	Insider Trans	1.71%	Shs Float	89.78M	Perf Month	5.24%
Income	-125.04M	PEG	-	EPS next Q	-0.20	Inst Own	36.90%	Short Float	10.55%	Perf Quarter	30.00%
Sales	0.00M	P/S	-	EPS this Y	-7.98%	Inst Trans	2.79%	Short Ratio	12.11	Perf Half Y	-5.96%
Book/sh	2.10	P/B	1.05	EPS next Y	-7.28%	ROA	-27.48%	Short Interest	9.48M	Perf Year	-22.73%
Cash/sh	2.06	P/C	1.07	EPS next 5Y	-	ROE	-34.33%	52W Range	1.51 - 3.38	Perf YTD	3.76%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-69.36%	ROI	-33.93%	52W High	-34.52%	Beta	1.08
Dividend TTM	-	Quick Ratio	12.26	Sales past 5Y	0.00%	Gross Margin	-	52W Low	46.36%	ATR (14)	0.14
Dividend Ex-Date	-	Current Ratio	12.26	EPS Y/Y TTM	57.42%	Oper. Margin	0.00%	RSI (14)	60.60	Volatility	6.30% 6.64%
Employees	126	Debt/Eq	0.18	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.38	Target Price	7.00
Option/Short	Yes / Yes	LT Debt/Eq	0.16	EPS Q/Q	81.42%	Payout	-	Rel Volume	0.58	Prev Close	2.14
Sales Surprise	-	EPS Surprise	11.74%	Sales Q/Q	-	Earnings	Mar 27 AMC	Avg Volume	782.42K	Price	2.21
SMA20	9.60%	SMA50	4.03%	SMA200	1.72%	Trades		Volume	450,103	Change	3.27%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-24	Initiated	CapitalOne	Overweight	$8
Jan-05-24	Downgrade	BofA Securities	Buy → Neutral	$11 → $6
Oct-11-23	Initiated	H.C. Wainwright	Buy	$10
Mar-30-23	Initiated	Mizuho	Buy	$9
Feb-24-23	Initiated	Goldman	Buy	$10
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$15

Apr-24-24 04:05PM	Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-23-24 12:00PM	Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Apr-01-24 04:56PM	Erasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 05:31AM	Erasca Inc (ERAS) Aligns with EPS Projections, Reveals Robust Balance Sheet and Key Clinical ... (GuruFocus.com)
Mar-27-24 10:53PM	ERAS Stock Earnings: Erasca Beats EPS for Q4 2023 (InvestorPlace)
08:30PM	Loading…
08:30PM	Erasca Announces $45 Million Oversubscribed Private Placement Financing (GlobeNewswire)
04:01PM	Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results (GlobeNewswire)
Feb-14-24 08:00AM	Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials (GlobeNewswire)
Feb-01-24 08:00AM	Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-03-24 08:00AM	Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-23 01:34PM	3 Penny Stocks Youll Regret Not Buying Soon: December Edition (InvestorPlace) -5.08%
Dec-11-23 08:00AM	Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma (GlobeNewswire)
Nov-28-23 08:00AM	Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway (GlobeNewswire) -11.38%
Nov-09-23 04:01PM	Erasca Reports Third Quarter 2023 Financial Results and Business Updates (GlobeNewswire) -8.64%
Nov-08-23 08:00AM	Erasca to Present at Upcoming Investor Conferences in November (GlobeNewswire)
11:28AM	Loading…
Oct-12-23 11:28AM	Insiders Are Betting Millions on These 2 Stocks Heres Why You Might Want to Follow Their Lead (TipRanks)
Oct-10-23 03:56PM	Why Shares of Erasca Are Jumping Tuesday (Motley Fool) +13.18%
Sep-19-23 08:00AM	Erasca to Present at the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-05-23 08:00AM	Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-29-23 08:00AM	Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors (GlobeNewswire)
Aug-10-23 04:01PM	Erasca Reports Second Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
Jul-12-23 06:35AM	Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation (Simply Wall St.)
Jun-22-23 04:01PM	Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma (GlobeNewswire) -7.96%
Jun-15-23 06:22AM	Jonathan Lim Spends US$275k On Erasca Stock \ (Simply Wall St.)
Jun-06-23 10:53AM	Erasca Puts Certain Pipeline Programs On Chopping Block To Focus On Programs With Encouraging Activity Signals (Benzinga) -8.18%
Jun-05-23 04:01PM	Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline (GlobeNewswire) +14.19%
Jun-01-23 08:00AM	Erasca to Present at Upcoming Investor Conferences (GlobeNewswire)
May-31-23 08:00AM	Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor (GlobeNewswire)
May-25-23 05:00PM	Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting (GlobeNewswire)
09:01AM	With 42% stake, Erasca, Inc. (NASDAQ:ERAS) seems to have captured institutional investors' interest (Simply Wall St.)
08:00AM	Loading…
May-16-23 08:00AM	Erasca Further Strengthens Business Leadership with Two Key Promotions (GlobeNewswire)
May-15-23 04:01PM	Erasca Reports First Quarter 2023 Financial Results and Business Updates (GlobeNewswire)
May-02-23 08:00AM	Erasca to Present at the Bank of America Securities 2023 Health Care Conference (GlobeNewswire)
May-01-23 08:00AM	Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma (GlobeNewswire)
Apr-26-23 05:00PM	Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-25-23 08:00AM	Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma (GlobeNewswire)
Apr-18-23 09:00AM	Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting (GlobeNewswire)
Apr-12-23 07:07AM	Daily Vickers Top Buyers & Sellers for 04/12/2023 (Argus Research)
Apr-10-23 08:00AM	Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage Development (GlobeNewswire) -8.83%
Mar-31-23 06:19AM	Trade Alert: The Co-Founder Of Erasca, Inc. (NASDAQ:ERAS), Jonathan Lim, Has Just Spent US$284k Buying A Few More Shares (Simply Wall St.)
Mar-30-23 04:21AM	6 analyst picks of the day: Walmart stock pops, Fluence upped to Buy \| Pro Recap (Investing.com)
Mar-23-23 04:01PM	Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates (GlobeNewswire)
Mar-14-23 04:31PM	Erasca Announces Poster Presentation at the 2023 AACR Annual Meeting (GlobeNewswire)
Feb-01-23 08:00AM	Erasca to Present at the Guggenheim Oncology Conference 2023 (GlobeNewswire)
Jan-16-23 06:19AM	We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth (Simply Wall St.)
Jan-11-23 03:04PM	11 Best All-Time Low Stocks To Buy Now (Insider Monkey) +8.00%
Jan-04-23 08:00AM	Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-22 08:00AM	Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid Tumors (GlobeNewswire)
Dec-17-22 07:28AM	Co-Founder Jonathan Lim Just Bought A Handful Of Shares In Erasca, Inc. (NASDAQ:ERAS) (Simply Wall St.)
Dec-16-22 07:15AM	Erasca, Inc.'s (NASDAQ:ERAS) recent 16% pullback adds to one-year year losses, institutional owners may take drastic measures (Simply Wall St.)
Dec-13-22 08:00AM	Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors (GlobeNewswire)
Dec-09-22 10:00AM	Erasca Oulicenses Its Mid-Stage Cancer Program To Novartis, Raises $100M Via Equity Offering (Benzinga) -22.30%
07:34AM	Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib (GlobeNewswire)
07:32AM	Erasca Announces Pricing of Underwritten Offering of Common Stock (GlobeNewswire)
Nov-30-22 08:00AM	Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination (GlobeNewswire) +6.34%
Nov-22-22 08:00AM	Erasca to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-14-22 09:55AM	Wall Street Analysts Predict a 126% Upside in Erasca, Inc. (ERAS): Here's What You Should Know (Zacks)
Nov-09-22 04:01PM	Erasca Reports Third Quarter 2022 Financial Results and Business Updates (GlobeNewswire)
Oct-20-22 08:00AM	Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination (GlobeNewswire)
Oct-12-22 08:00AM	Erasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR Symposium (GlobeNewswire)
Sep-26-22 08:00AM	Erasca to Present at the Bank of America Securities Precision Oncology Conference 2022 (GlobeNewswire)
Sep-09-22 08:31AM	Erasca to Present at the Morgan Stanley Global Healthcare Conference (GlobeNewswire)
Sep-08-22 11:08AM	Erasca Touts Promising Early Data From Lead Cancer Programs (Benzinga) -11.28%
Sep-07-22 04:05PM	Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future Combination Trials (GlobeNewswire) +6.21%
Aug-24-22 08:00AM	Erasca to Host R&D Day with KOL Dr. David Hong on Lead Clinical Programs ERAS-007 and ERAS-601 in Advanced Solid Tumors (GlobeNewswire)
Aug-23-22 09:55AM	Here's Why Erasca, Inc. (ERAS) Looks Ripe for Bottom Fishing (Zacks) +5.08%
08:00AM	Erasca and MD Anderson Announce Strategic Research and Development Collaboration in RAS/MAPK-Driven Cancers (GlobeNewswire)
Aug-19-22 09:55AM	Wall Street Analysts See an 111% Upside in Erasca, Inc. (ERAS): Can the Stock Really Move This High? (Zacks) -5.56%
Aug-11-22 04:05PM	Erasca Reports Second Quarter 2022 Financial Results and Business Updates (GlobeNewswire) -11.12%
Aug-08-22 09:29AM	Here's Why We're Not Too Worried About Erasca's (NASDAQ:ERAS) Cash Burn Situation (Simply Wall St.)
Aug-03-22 09:55AM	Wall Street Analysts Believe Erasca, Inc. (ERAS) Could Rally 244%: Here's is How to Trade (Zacks)
Jul-27-22 06:00PM	Erasca, Inc. (ERAS) Gains But Lags Market: What You Should Know (Zacks)
Jul-21-22 06:00PM	Erasca, Inc. (ERAS) Stock Sinks As Market Gains: What You Should Know (Zacks)
Jul-18-22 06:15PM	Erasca, Inc. (ERAS) Gains As Market Dips: What You Should Know (Zacks)
09:55AM	Wall Street Analysts See a 288% Upside in Erasca, Inc. (ERAS): Can the Stock Really Move This High? (Zacks)
08:00AM	Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 and Cetuximab Combination (GlobeNewswire)
Jul-12-22 06:00PM	Erasca, Inc. (ERAS) Stock Moves -0.32%: What You Should Know (Zacks)
Jul-06-22 06:15PM	Erasca, Inc. (ERAS) Outpaces Stock Market Gains: What You Should Know (Zacks)
Jun-09-22 09:55AM	Wall Street Analysts Believe Erasca, Inc. (ERAS) Could Rally 362%: Here's is How to Trade (Zacks)
Jun-03-22 09:00AM	Erasca to Present at the 2022 Jefferies Healthcare Conference (GlobeNewswire) +13.23%
Jun-02-22 08:00AM	Erasca Announces Trial to Evaluate ERAS-007 in Combination with KRAS G12C Inhibitor in KRAS-Driven Cancers (GlobeNewswire)
May-25-22 08:00AM	Erasca Strengthens Clinical and Commercial Leadership with Three Key Appointments (GlobeNewswire)
May-23-22 09:55AM	Erasca, Inc. (ERAS) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
May-12-22 04:01PM	Erasca Reports First Quarter 2022 Financial Results and Business Updates (GlobeNewswire)
May-03-22 08:00AM	Erasca to Present at the Bank of America Securities 2022 Healthcare Conference (GlobeNewswire)
Apr-27-22 08:00AM	Erasca Appoints Jean Liu to its Board of Directors (GlobeNewswire)
Apr-15-22 07:42AM	Insiders at Erasca, Inc. (NASDAQ:ERAS) recouped some losses this week after buying this year, still down US$111k (Simply Wall St.)
Apr-12-22 04:01PM	Erasca Presents Compelling Preclinical Data Supporting Clinical Development of Potentially Best-In-Class Programs ERAS-007, ERAS-601, and ERAS-3490 at 2022 AACR Annual Meeting (GlobeNewswire)
Apr-06-22 08:00AM	Erasca To Host Investor Event with Leading KOL Dr. Scott Kopetz on Therapeutic Opportunities in Cancers Driven by the RAS/MAPK Pathway (GlobeNewswire)
Mar-24-22 04:05PM	Erasca Reports Fourth Quarter 2021 Financial Results and Business Updates (GlobeNewswire)
Mar-10-22 08:00AM	Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-007 and Cetuximab Combination (GlobeNewswire)
Mar-08-22 04:31PM	Erasca Announces Six Poster Presentations at the 2022 AACR Annual Meeting (GlobeNewswire)
Mar-01-22 04:14PM	SLR Investment Corp. Announces Quarter and Fiscal Year Ended December 31, 2021 Financial Results; (GlobeNewswire)
Feb-08-22 09:04AM	Is a Surprise Coming for Erasca (ERAS) This Earnings Season? (Zacks)
Feb-03-22 08:00AM	Erasca to Present at the Guggenheim Healthcare Talks 2022 Oncology Day (GlobeNewswire)
Jan-27-22 01:38PM	Edmonds Duncan Registered Investment Advisors, LLC Buys VanEck Vectors Semiconductor ETF, ... (GuruFocus.com)
Jan-18-22 08:00AM	Erasca Strengthens Leadership Team with Two Key Executive Appointments (GlobeNewswire) -5.95%
Jan-04-22 08:00AM	Erasca to Present at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-24-21 12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... (GuruFocus.com)
Dec-18-21 12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... (GuruFocus.com)

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim on July 1, 2018 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lim Jonathan E	Chairman & CEO	Dec 06 '23	Buy	1.72	278,150	478,418	12,899,360	Dec 06 07:41 PM
Start Valerie Denise Harding	Director	Dec 06 '23	Buy	1.85	10,000	18,480	20,000	Dec 08 09:10 AM
Lim Jonathan E	Chairman & CEO	Dec 05 '23	Buy	1.69	721,850	1,217,761	12,899,360	Dec 06 07:41 PM
Casdin Alexander W.	Director	Dec 04 '23	Buy	1.66	30,000	49,785	493,974	Dec 04 06:23 PM
Lim Jonathan E	Chairman & CEO	Oct 05 '23	Buy	2.03	1,000,000	2,026,000	19,456,216	Oct 10 08:00 AM
Lim Jonathan E	Chairman & CEO	Jun 08 '23	Buy	2.75	100,000	275,000	18,396,216	Jun 08 08:54 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

HLXB

Helix Acquisition Corp. II

MLTX

MoonLake Immunotherapeutics

BMEA

Biomea Fusion Inc

ERAS

Erasca Inc

Upgrade your FINVIZ experience